Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 214
- Registration Number
- NCT02953639
- Locations
- 🇺🇸
Booker, J. Gary, MD, APMC, Shreveport, Louisiana, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States
Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia
- Conditions
- Breast Cancer
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 351
- Registration Number
- NCT02954471
- Locations
- 🇸🇦
King Faisal Specialist Hospital & Research Centre, Jeddah, Saudi Arabia
🇸🇦King Fahad Specialist Hospital; Oncology, Dammam, Saudi Arabia
🇸🇦National Guard King Abdulaziz Medical City; Oncology, Riyadh, Saudi Arabia
Monitoring of Multiple Sclerosis (MS) Participants With the Use of Digital Technology (Smartphones and Smartwatches) - A Feasibility Study
- Conditions
- Multiple Sclerosis
- Interventions
- Device: Smartphone and Smartwatch
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT02952911
- Locations
- 🇪🇸
Hospital Vall d'Hebron; Servicio de Neurología, Barcelona, Spain
🇺🇸UCSF- Multiple Sclerosis Centre; Department of Neurology, San Francisco, California, United States
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 192
- Registration Number
- NCT02952924
- Locations
- 🇳🇿
Auckland Clinical Studies Limited, Grafton, New Zealand
🇸🇬National University Health System, Singapore, Singapore
🇸🇬Singapore General Hospital, Singapore, Singapore
Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 177
- Registration Number
- NCT02951429
- Locations
- 🇳🇱
Vu Medisch Centrum; Afdeling Longziekten, Amsterdam, Netherlands
🇹🇷Yedikule Gogus Hastaliklari ve Gogus Cerrahisi EAH;Gogus Hastaliklari, Istanbul, Turkey
🇿🇦University of Stellenbosch; Respiratory Research, Parow, South Africa
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 119
- Registration Number
- NCT02951767
- Locations
- 🇺🇸
USC Norris Cancer Center, Los Angeles, California, United States
🇺🇸Kaiser Permanente; Oncology Clinical Trials, Vallejo, California, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke
- First Posted Date
- 2016-10-10
- Last Posted Date
- 2019-01-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 5
- Registration Number
- NCT02928393
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇫🇷CHU de Besancon Hopital Jean Minjoz; Service de Neurologie, Besançon, France
🇫🇷Hopital Gabriel Montpied CHU de Clermont-Ferrand; Service de Neurologie B, Clermont-Ferrand, France
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
- First Posted Date
- 2016-10-10
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1004
- Registration Number
- NCT02928406
- Locations
- 🇪🇪
North Estonia Medical Centre Foundation; Oncology Center, Tallinn, Estonia
🇨🇭Hôpitaux Universit. de Genève Médecine Oncologie; Oncologie, Geneve, Switzerland
🇨🇭Luzerner Kantonsspital; Medizinische Onkologie, Luzern, Switzerland
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 202
- Registration Number
- NCT02924883
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇩🇪Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, Heidelberg, Germany
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2022-12-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 517
- Registration Number
- NCT02918019
- Locations
- 🇺🇸
Genesis Clinical Research & Consulting, LLC, Fall River, Massachusetts, United States
🇨🇦Cheema Research, Mississauga, Ontario, Canada
🇺🇸Emerald Coast Research Associates, Panama City, Florida, United States